Joel Schuman is an Ophthalmology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Wills Eye Hospital
840 Walnut Street
Philadelphia, PA 19107
Telephone
215-825-4790Provider last certified this registry record 19 Feb 2025.
Clinical trials
- Electrical Stimulation for the Treatment of Glaucoma
Sponsor: Stanford University
- A Study Using Transorbital Alternating Current Stimulation for People With Glaucoma
Sponsor: NYU Langone Health
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Bausch & Lomb Americas Inc.Program year20252 payments
- EyePoint Pharmaceuticals US, Inc.Program year20241 payment
- Johnson & Johnson Surgical Vision, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
89.3%Prostaglandin Analog27.6%Latanoprost87%Lumigan14%Part D≥110 patientsCarbonic Anhydrase Inhibitor23.7%Dorzolamide-Timolol69%Simbrinza12%Dorzolamide Hcl12%Brinzolamide6%Part D<11 patients+ 7 more classes in this area
Cardiovascular
6%Beta blocker6%Timolol Maleate100%Part D≥33 patientsMetabolism & gastrointestinal
1.8%Anticholinergic1.8%Atropine Sulfate100%Part D≥17 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2003–2025 per NIH RePORTER. The latest:
- Novel Glaucoma Diagnostics for Structure and Function.
Wills Eye Health System
FY2025$1,047,658R01EY013178 - Novel Glaucoma Diagnostics for Structure and Function.
Wills Eye Health System
FY2024$1,308,371R01EY013178 - Novel Glaucoma Diagnostics for Structure and Function - Renewal - 1
Wills Eye Health System
FY2023$687,519R01EY013178
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”